Evidence map›Paper›PMID 34215929›Full record

Observational studyJournal of gastroenterology2021

Medical costs according to the stages of colorectal cancer: an analysis of health insurance claims in Hachioji, Japan.

Takahiro Utsumi, Takahiro Horimatsu, Yoshitaka Nishikawa, Nobuaki Hoshino, Yoshimitsu Takahashi, Rei Goto, Soichiro Kashihara, Jun Fukuyoshi, Takeo Nakayama, Hiroshi Seno

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Observational
  8. Observational
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Takahiro UtsumiDepartment of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan. tk_utsumi@kuhp.kyoto-u.ac.jp.ORCID 0000-0001-6067-3694
Takahiro HorimatsuInstitute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital, Kyoto, Japan.
Yoshitaka NishikawaDepartment of Health Informatics, Kyoto University School of Public Health, Kyoto, Japan.ORCID 0000-0003-3313-1990
Nobuaki HoshinoDepartment of Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Yoshimitsu TakahashiDepartment of Health Informatics, Kyoto University School of Public Health, Kyoto, Japan.
Rei GotoGraduate School of Business Administration, Keio University, Yokohama, Japan.
Soichiro KashiharaCancerscan, Co., Ltd., Tokyo, Japan.
Jun FukuyoshiCancerscan, Co., Ltd., Tokyo, Japan.
Takeo NakayamaDepartment of Health Informatics, Kyoto University School of Public Health, Kyoto, Japan.
Hiroshi SenoDepartment of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough the effect of the early detection of colorectal cancer (CRC) on medical costs needs to be clarified, there are few reports on the actual medical costs of CRC patients in Japan. We aimed to identify medical costs according to CRC stage, using health insurance claims.

methodsThis observational study included CRC patients who had received specific treatment for CRC, which was defined by the procedure code and the claim computer processing system code associated with the treatment of CRC. CRC patients who underwent endoscopic or radical surgical treatment were defined as the curable group and those with palliative treatment, including palliative chemotherapy, as the non-curable group. Total medical costs and medical costs of specific treatments for CRC for 3 years were measured using the claims held by Hachioji City from May 2014 to July 2019.

resultsThis study included 442 patients in the curable group, including 267 patients who underwent endoscopic treatment, and 175 patients who underwent radical surgical treatment, and 161 patients in the non-curable group. The mean (standard deviation) total medical costs in the curable and non-curable groups were 2,130 (2,494) and 8,279 (5,600) thousand Japanese Yen (JPY), respectively. The mean (standard deviation) medical costs for the specific treatment of CRC in the curable and non-curable groups were 408 (352) and 3,685 (3,479) thousand JPY, respectively.

conclusionsWe clarified the actual medical costs of CRC in curable and non-curable groups. These results suggest the effect of early detection of CRC in reducing medical costs.

Indexed as

AdultAgedColorectal NeoplasmsFemaleHealth Care CostsHumansInsurance Claim ReviewInsurance, HealthJapanMaleMiddle AgedNeoplasm StagingColorectal cancerEarly detectionHealth insurance claimsMedical costs

Identifiers

PMID34215929

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.